{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:36Z","timestamp":1793386476790,"version":"4.5.0"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ravulizumab, an anti\u2010complement C5 monoclonal antibody, was efficacious with acceptable safety in the randomized controlled period (RCP) and interim open\u2010label extension (OLE) periods of the CHAMPION MG phase 3 trial in adults with anti\u2010acetylcholine receptor antibody\u2010positive (AChR\u2010Ab+) generalized myasthenia gravis (gMG). Here, we report final results from the OLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who completed the 26\u2010week RCP could enter the OLE and receive ravulizumab for up to 4\u2009years. Efficacy and safety were assessed throughout the OLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among all ravulizumab\u2010treated patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009169; median [range] ravulizumab treatment, 759.0 [14.0, 1265.0] days), 161 entered the OLE (ravulizumab\u2010ravulizumab:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200978; placebo\u2010ravulizumab:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200983). Sustained improvements were observed in Myasthenia Gravis Activities of Daily Living (MG\u2010ADL) total scores (ravulizumab\u2010ravulizumab, least squares mean [95% CI] change from RCP baseline at week 164: \u22124.0 [\u22125.3, \u22122.8];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001; placebo\u2010ravulizumab, change from OLE baseline after 138\u2009weeks of treatment: \u22122.1 [\u22123.3, \u22120.9];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0005). One hundred and forty\u2010one out of 160 (88.1%) patients achieved a\u2009\u2265\u20092\u2010point improvement in MG\u2010ADL total score, and 59\/141 (41.8%) achieved a score of 0 or 1; once achieved, 32\/59 (54.2%) sustained this status for &gt;\u200950% of their remaining time in the study. Similar improvements were observed in Quantitative Myasthenia Gravis and Myasthenia Gravis Quality of Life\u201015 revised scores, and Neurological Quality of Life Fatigue subscale scores. Clinical deterioration event rates were reduced in the OLE versus placebo in the RCP. Corticosteroid usage was reduced in the OLE. Ravulizumab was well tolerated; no meningococcal infections were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ravulizumab demonstrated clinically meaningful and durable efficacy and safety in adults with AChR\u2010Ab+ gMG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.70158","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T01:34:21Z","timestamp":1744853661000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Long\u2010Term Efficacy and Safety of Ravulizumab in Adults With Anti\u2010Acetylcholine Receptor Antibody\u2010Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open\u2010Label Extension"],"prefix":"10.1111","volume":"32","author":[{"given":"Tuan H.","family":"Vu","sequence":"first","affiliation":[{"name":"University of South Florida Morsani College of Medicine  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Neurologico Carlo Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djillali","family":"Annane","sequence":"additional","affiliation":[{"name":"H\u00f4pital Raymond Poincar\u00e9, Garches University Paris Saclay\u2014UVSQ  Garches France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9453-9311","authenticated-orcid":false,"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[{"name":"Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-5342","authenticated-orcid":false,"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Nicolle","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-4883","authenticated-orcid":false,"given":"Vera","family":"Bril","sequence":"additional","affiliation":[{"name":"Ellen &amp; Martin Prosserman Centre for Neuromuscular Diseases, University Health Network University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Aguzzi","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Frick","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-8617","authenticated-orcid":false,"suffix":"Jr","given":"James F.","family":"Howard","sequence":"additional","affiliation":[{"name":"The University of North Carolina at Chapel Hill School of Medicine  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the CHAMPION MG Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010019\u20100079\u2010y"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311\u2010015\u20100398\u2010y"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00981"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2014.11.022"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596981"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001169"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8206.1"},{"key":"e_1_2_11_10_1","volume-title":"Soliris (Eculizumab) [Prescribing Information]","year":"2025"},{"key":"e_1_2_11_11_1","volume-title":"Soliris (Eculizumab) [European Public Assessment Report]","year":"2025"},{"key":"e_1_2_11_12_1","volume-title":"Ultomiris (Ravulizumab) [European Public Assessment Report]","year":"2024"},{"key":"e_1_2_11_13_1","volume-title":"Ultomiris (Ravulizumab) [Prescribing Information]","year":"2024"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201009\u2010876136"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010023\u201011699\u2010x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.035"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010023\u201011617\u20101"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.7.1487"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749\u20106632.1998.tb11015.x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25198"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136\u2010011\u20109958\u20108"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22140"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010020\u201009770\u2010y"},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","unstructured":"T.Vu R.Mantegazza D.Annane et\u00a0al. \u201cLong\u2010Term Efficacy and Safety of Ravulizumab a Long\u2010Acting Terminal Complement Inhibitor in Adults with AChR Ab+ Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open\u2010Label Extension \u201dAmerican Academy of Neurology Annual Meeting 2024; April 13\u201318 2024; Denver CO. OP 010.","DOI":"10.1212\/WNL.0000000000204620"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27791"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27992"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer\u20102023\u20100108"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1140743"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.11477\/mf.1416202551"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.556104"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52051"},{"key":"e_1_2_11_34_1","doi-asserted-by":"crossref","unstructured":"M.Pulley S.Macwan R.Nowak et\u00a0al. \u201cChange in Concomitant Therapies for Generalized Myasthenia Gravis in Patients Receiving Eculizumab: A Retrospective Analysis of Registry Data \u201dAmerican Academy of Neurology (AAN) 2023 Annual Meeting; April 22\u201327 2023; Boston MA USA. Poster 1.5\u2010002.","DOI":"10.1212\/WNL.0000000000202372"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26447"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474\u20104422(17)30369\u20101"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.70158","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:59:07Z","timestamp":1791201547000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/ene.70158"],"URL":"https:\/\/doi.org\/10.1111\/ene.70158","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-12-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70158"}}